Literature DB >> 17298766

Crohn's disease of the esophagus.

Kim L Isaacs1.   

Abstract

Esophageal damage is an uncommon manifestation of Crohn's disease. The diagnosis should be considered in patients who have other intestinal manifestations of Crohn's disease and present with esophageal symptoms. Diagnosis should be based on history, known extraesophageal Crohn's disease, endoscopic evaluation with biopsy, and exclusion of gastroesophageal reflux disease. Mild disease should be treated with acid suppression and a short course of steroids. 5-aminosalicylates are not likely to be effective due to drug release characteristics. Patients who have moderate to severe disease should be treated aggressively with acid suppression, a longer course of steroids, and consideration of immunosuppressive therapy with 6-mercaptopurine or azathioprine. Infliximab or other anti-tumor necrosis factor therapy also can be considered in refractory patients to try to prevent the complications of stricturing and fistula formation. In those patients who develop strictures of the esophagus, treatment with balloon dilatation of the stricture followed by injection of a long-acting steroid such as triamcinolone will help to alleviate symptoms. Surgery may be required for severe, refractory symptoms, but it has a high morbidity in this population.

Entities:  

Year:  2007        PMID: 17298766     DOI: 10.1007/s11938-007-0058-3

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  56 in total

1.  Infliximab treatment of an esophagobronchial fistula in a patient with extensive Crohn's disease of the esophagus.

Authors:  Immanuel K Ho; Denise P Guarino; Yuriy Pertsovskiy; Maurice A Cerulli
Journal:  J Clin Gastroenterol       Date:  2002-04       Impact factor: 3.062

2.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

3.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  Oesophago-bronchial fistula causing cough and recurrent lower respiratory tract infections in a patient with Crohn's disease.

Authors:  J Brittenden; H S R Hosker; C Healey; G Porter
Journal:  Hosp Med       Date:  2005-05

Review 5.  Inflammatory bowel disease: current therapeutic options.

Authors:  Eugeni Domènech
Journal:  Digestion       Date:  2006-02-08       Impact factor: 3.216

6.  Treatment of esophageal Crohn's disease by enteral feeding via percutaneous endoscopic gastrostomy.

Authors:  T S Thomas; E Berto; M L Scribano; S J Middleton; J O Hunter
Journal:  JPEN J Parenter Enteral Nutr       Date:  2000 May-Jun       Impact factor: 4.016

7.  The natural history of esophageal Crohn's disease: three patterns of evolution.

Authors:  G D'Haens; P Rutgeerts; K Geboes; G Vantrappen
Journal:  Gastrointest Endosc       Date:  1994 May-Jun       Impact factor: 9.427

8.  Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures.

Authors:  A Ferlitsch; W Reinisch; A Püspök; C Dejaco; M Schillinger; R Schöfl; R Pötzi; A Gangl; H Vogelsang
Journal:  Endoscopy       Date:  2006-05       Impact factor: 10.093

Review 9.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 10.  Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.

Authors:  Marla C Dubinsky
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

View more
  2 in total

1.  Double-Edged Sword: Esophageal and Colonic Crohn's Disease.

Authors:  Apurva Tandon; Charles Lombard; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2015-08-30       Impact factor: 3.199

2.  Adult-Onset Esophageal Crohn's Disease.

Authors:  George Kasarala; Glenn Harvin; Sam Durrett
Journal:  ACG Case Rep J       Date:  2016-10-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.